A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants

Project Details

StatusActive
Effective start/end date8/11/167/11/21

Funding

  • MedImmune, LLC: $38,528.20

Keywords

  • Biotechnology & Drug Development, Immunology